On July 23, 2019, Amgen, maker of the cancer treatment drug Neupogen (filgrastim), filed patent infringement claims in the Southern District of California against Tanvex Biopharma over Tanvex’s ...
“The U.S. approval of our first biosimilar is a very significant milestone for Amneal. Biosimilars represent the next wave of providing access to affordable medicines in the U.S.” Chirag and Chintu ...
PISCATAWAY, N.J.--(BUSINESS WIRE)--U.S.-based Adello Biologics today announced that U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) ...
Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings. Objectives: ...
Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...
The U.S. FDA approved three biosimilar products from Samsung Bioepis Co. Ltd., Tanvex Biopharma Inc. and Formycon AG as follow-on biologics to Stelara (ustekinumab), Neupogen (filgrastim) and Eylea ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...
Prospective study comparing Broviac cuffed catheter and implantable vascular access device for adjuvant and neoadjuvant chemotherapy for breast cancer : infectious and mechanical risks This is an ASCO ...
Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback